国药控股：国药股份前三季度归母净利润14.92亿元 同比增长0.74%

Group 1 - The core viewpoint of the article is that China National Pharmaceutical Group (国药控股) has reported its subsidiary China National Pharmaceutical Co., Ltd. (国药股份) financial performance for the first three quarters of 2025, showing modest growth in revenue and net profit [1] Group 2 - The company achieved a revenue of 39.381 billion yuan, representing a year-on-year increase of 3.56% [1] - The net profit attributable to shareholders of the listed company was 1.492 billion yuan, reflecting a year-on-year growth of 0.74% [1] - The non-recurring net profit was 1.47 billion yuan, which indicates a year-on-year decline of 1.27% [1] - The basic earnings per share stood at 1.9778 yuan [1]